Total Payments
$638,608
2024 Payments
$65,665
Companies
101
Transactions
2,941
Medicare Patients
6,952
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$425,262 (66.6%)
Research$110,555 (17.3%)
Food & Beverage$51,610 (8.1%)
Travel$29,659 (4.6%)
Consulting$21,355 (3.3%)
Education$167.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $390,868 | 287 | 61.2% |
| Unspecified | $110,555 | 22 | 17.3% |
| Food and Beverage | $51,610 | 2,435 | 8.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $29,930 | 39 | 4.7% |
| Travel and Lodging | $29,659 | 137 | 4.6% |
| Consulting Fee | $21,355 | 13 | 3.3% |
| Honoraria | $4,420 | 2 | 0.7% |
| Education | $167.61 | 5 | 0.0% |
| Grant | $43.95 | 1 | 0.0% |
Payments by Type
General
$528,053
2,919 transactions
Research
$110,555
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $96,800 | 233 | $0 (2024) |
| Allergan, Inc. | $88,218 | 266 | $0 (2022) |
| Amgen Inc. | $79,442 | 182 | $0 (2024) |
| ABBVIE INC. | $78,660 | 261 | $0 (2024) |
| PFIZER INC. | $44,065 | 52 | $0 (2024) |
| Eisai Inc. | $40,421 | 107 | $0 (2024) |
| GRT US Holding, Inc. | $40,339 | 5 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $27,179 | 153 | $0 (2024) |
| Eli Lilly and Company | $20,998 | 7 | $0 (2023) |
| Depomed, Inc. | $20,823 | 43 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,665 | 372 | Eisai Inc. ($33,763) |
| 2023 | $74,790 | 287 | PFIZER INC. ($43,417) |
| 2022 | $40,545 | 345 | ABBVIE INC. ($12,291) |
| 2021 | $115,363 | 421 | Lilly USA, LLC ($23,667) |
| 2020 | $93,273 | 380 | Lilly USA, LLC ($51,864) |
| 2019 | $117,238 | 344 | Amgen Inc. ($42,289) |
| 2018 | $71,117 | 429 | Allergan Inc. ($22,249) |
| 2017 | $60,617 | 363 | Depomed, Inc. ($20,823) |
All Payment Transactions
2,941 individual payment records from CMS Open Payments — Page 1 of 118
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SpringWorks Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $17.79 | General |
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $2.27 | General |
| Category: Neurology | ||||||
| 12/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Neurology | ||||||
| 12/16/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Analgesic | ||||||
| 12/16/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $912.50 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $365.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: EPILEPSY | ||||||
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,190.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $912.50 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $912.50 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $367.25 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $365.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $92.02 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Neurology | ||||||
| 12/09/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Genetic Disease | ||||||
| 12/07/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: Analgesic | ||||||
| 12/06/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: Analgesic | ||||||
| 12/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KF7013-02 | GRT US Holding, Inc. | $40,339 | 5 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $21,642 | 2 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $21,575 | 7 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $10,182 | 3 |
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $6,463 | 1 |
| 15-AVP-786-301 | Avanir Pharmaceuticals, Inc. | $6,000 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $3,073 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $980.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,734 | 153,554 | $4.1M | $699,793 |
| 2022 | 29 | 1,547 | 50,027 | $2.4M | $490,886 |
| 2021 | 26 | 1,834 | 46,353 | $2.4M | $469,457 |
| 2020 | 24 | 1,837 | 39,449 | $2.1M | $406,347 |
Total Patients
6,952
Total Services
289,383
Medicare Billing
$2.1M
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 67 | 38,400 | $921,600 | $190,766 | 20.7% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 18 | 10,700 | $331,700 | $144,281 | 43.5% |
| J0174 | Injection, lecanemab-irmb, 1 mg | Office | 2023 | 21 | 101,664 | $1.4M | $106,718 | 7.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 380 | 638 | $358,556 | $60,515 | 16.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 254 | 361 | $284,468 | $51,928 | 18.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 57 | 171 | $132,012 | $22,460 | 17.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 169 | 169 | $123,370 | $22,101 | 17.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 45 | 171 | $107,046 | $18,162 | 17.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 103 | 142 | $61,486 | $11,218 | 18.2% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 62 | 63 | $60,480 | $10,703 | 17.7% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 108 | 178 | $49,840 | $8,879 | 17.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 36 | 153 | $47,430 | $7,979 | 16.8% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 34 | 34 | $44,574 | $7,888 | 17.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 41 | 41 | $32,923 | $5,827 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $21,472 | $3,822 | 17.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $21,736 | $3,626 | 16.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 14 | 14 | $15,616 | $3,005 | 19.2% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 23 | 31 | $15,351 | $2,631 | 17.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 24 | 24 | $14,568 | $2,608 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 39 | $15,483 | $2,502 | 16.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 12 | 145 | $13,485 | $2,406 | 17.8% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 11 | 11 | $12,276 | $2,210 | 18.0% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 16 | 33 | $11,484 | $2,053 | 17.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 51 | $6,732 | $1,172 | 17.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $6,193 | $1,140 | 18.4% |
About Dr. Brian Costell, M.D
Dr. Brian Costell, M.D is a Neurology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174563688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Costell, M.D has received a total of $638,608 in payments from pharmaceutical and medical device companies, with $65,665 received in 2024. These payments were reported across 2,941 transactions from 101 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($390,868).
As a Medicare-enrolled provider, Costell has provided services to 6,952 Medicare beneficiaries, totaling 289,383 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Epilepsy
- Location Boca Raton, FL
- Active Since 06/07/2006
- Last Updated 06/12/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174563688
Products in Payments
- BOTOX (Biological) $81,489
- Aimovig (Biological) $77,941
- EMGALITY (Drug) $56,815
- UBRELVY (Drug) $53,476
- NURTEC ODT (Drug) $45,196
- Neridronic acid (Drug) $40,339
- Leqembi (Drug) $39,938
- REYVOW (Drug) $33,104
- Cambia (Drug) $31,669
- ZAVZPRET (Drug) $21,642
- TROKENDI XR (Drug) $16,202
- QULIPTA (Drug) $14,299
- AJOVY (Biological) $12,021
- BOTOX (Drug) $11,498
- AJOVY (Drug) $10,246
- APTIOM (Drug) $7,082
- VYEPTI (Biological) $4,843
- OXTELLAR XR (Drug) $3,145
- VYVGART (Drug) $2,290
- FIRDAPSE (Drug) $1,689
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Boca Raton
Dr. Stuart Isaacson, Md, MD
Neurology — Payments: $4.9M
Neurology $4.9M
Brian Steingo, Md, MD
Neurology — Payments: $1.4M
Neurology $1.4M
Dr. Patricio Espinosa, Md,Mph, MD,MPH
Neurology — Payments: $215,050
Neurology $215,050
Dr. Richard Isaacson, M.d, M.D
Neurology — Payments: $140,056
Neurology $140,056
Gediminas Gliebus, M.d, M.D
Neurology — Payments: $120,507
Neurology $120,507
Dr. Richard Dewey, Md, MD
Neurology — Payments: $45,477
Neurology $45,477